The company said net sales for Q1 2024 (ended March 31) were $1,598.2 million, up 9.5% from $1,459.6 million a year earlier. It cited 10% growth on both a reported basis and a constant currency basis.

1. 01

   The company said net sales for Q1 2024 (ended March 31) were $1,598.2 million, up 9.5% from $1,459.6 million a year earlier. It cited 10% growth on both a reported basis and a constant currency basis.

2. 02

   Edwards said TAVR sales for Q1 were $1.0 billion, up 6% (8% on a constant currency basis adjusted for billing days), and TMTT sales were $73 million, up 75%.

3. 03

   The company said net income attributable to Edwards Lifesciences for Q1 was $351.9 million, diluted earnings per share (EPS) was $0.58, and adjusted EPS was $0.66. Its adjustments included separation costs of $41.3 million.

4. 04

   The company said it expects full-year 2024 sales growth to be at the high end of its prior outlook of 8 to 10% ($6.3 to $6.6 billion). It also outlined Q2 sales of $1.62 to $1.70 billion and adjusted EPS of $0.67 to $0.71.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.